Conagra Brands, Inc. (CAG) Income Statement

The revenue trajectory is unambiguously contracting: even the strongest quarter in the series (-0.4% in 2025Q2) was still negative, while the worst (-6.8% in 2026Q2) coincided with a significant earnings miss. The improving trend in the most recent four quarters — from -6.8% to -1.4% — may suggest the rate of decline is moderating, but the fact that it remains negative implies management's guidance of -3% to -1% organic net sales for FY2027 implicitly assumes no volume recovery this year. Given that the company's frozen and grocery staples portfolio historically exhibited defensive demand, the persistent contraction may indicate consumers are either trading down to private label or reducing branded frozen purchases more broadly.

The margin trajectory is monotonic and structurally concerning: each sequential period has either declined or held roughly flat, with no quarter showing a recovery above the prior year's level. This pattern appears inconsistent with a temporary commodity input cost story and more consistent with a structural inability to pass through inflation into a price-sensitive frozen meal category. Given that competitors like Kellanova and McCormick maintain gross margins in the 37% range, the ~24% level reported by Conagra may reflect a portfolio mix skewed toward lower-margin center-store staples where private label substitution risk is highest. Investors should monitor whether any stabilization in gross margins occurs alongside improving revenue, which would indicate pricing has found a floor.

Excluding the 2024Q4 anomaly, SG&A appears to have trended modestly lower as a percentage of revenue, falling from roughly 13.3% ($387.4M / $2.9B) in 2024Q3 to approximately 13.3% ($350.3M / $2.6B) in 2027Q1, indicating cost control has roughly kept pace with revenue contraction rather than compounding operating leverage losses. However, the fact that R&D was $0 in seven of the ten quarters while appearing in only three (2025Q4 at $60.8M and 2024Q4 at $61.4M) raises the question of whether innovation spend is being deferred or whether the accounting treatment has changed. If the latter, this could mean true R&D intensity is higher than the intermittent figures suggest, and the apparent expense discipline may be less robust than it appears.